202 related articles for article (PubMed ID: 29063896)
1.
Sahu M; Saseedharan S; Bhalekar P
Indian J Med Microbiol; 2017; 35(3):437-438. PubMed ID: 29063896
[No Abstract] [Full Text] [Related]
2. Fosfomycin: an oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms.
Hutley EJ; Chand MA; Hounsome G; Kelsey MC
J Infect; 2010 Apr; 60(4):308-9. PubMed ID: 20114062
[No Abstract] [Full Text] [Related]
3. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.
Pogue JM; Marchaim D; Abreu-Lanfranco O; Sunkara B; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Martin ET; Dhar S; Kaye KS; Lephart PR
J Antibiot (Tokyo); 2013 Oct; 66(10):625-7. PubMed ID: 23715037
[No Abstract] [Full Text] [Related]
4. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
5. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
Deshpande P; Rodrigues C; Shetty A; Kapadia F; Hedge A; Soman R
J Assoc Physicians India; 2010 Mar; 58():147-9. PubMed ID: 20848811
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.
Sahni RD; Balaji V; Varghese R; John J; Tansarli GS; Falagas ME
Future Microbiol; 2013 May; 8(5):675-80. PubMed ID: 23642120
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance mediated by co-carriage of extended-spectrum beta-lactamases, AmpC and New Delhi metallo-beta-lactamase-1 genes among carbapenem-resistant Enterobacteriaceae at five Indian medical centres.
Manoharan A; Barla GS; Peter R; Sugumar M; Mathai D
Indian J Med Microbiol; 2016; 34(3):359-61. PubMed ID: 27514962
[TBL] [Abstract][Full Text] [Related]
8. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of quinolone-resistant Enterobacteriaceae uropathogens to fosfomycin trometamol, in Dakar, Senegal.
Nabeth P; Perrier-Gros-Claude JD; Juergens-Behr A; Dromigny JA
Scand J Infect Dis; 2005; 37(6-7):497-9. PubMed ID: 16012011
[TBL] [Abstract][Full Text] [Related]
10. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
[TBL] [Abstract][Full Text] [Related]
11. Emerging carbapenem resistance in the context of a new metallo-beta-lactamase (NDM-1).
Basu S; Singh AK; Nair GB
Natl Med J India; 2010; 23(5):261-2. PubMed ID: 21250578
[No Abstract] [Full Text] [Related]
12. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
Garau J
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
[TBL] [Abstract][Full Text] [Related]
13. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options.
Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM
Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
[TBL] [Abstract][Full Text] [Related]
15. [Laboratory detection of carbapenemase-producing Enterobacteriaceae].
Cercenado E
Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():8-11. PubMed ID: 26365726
[TBL] [Abstract][Full Text] [Related]
16. "Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla
Rosa R; Rudin SD; Rojas LJ; Hujer AM; Perez-Cardona A; Perez F; Bonomo RA; Martinez O; Abbo LM; Camargo JF
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29064133
[TBL] [Abstract][Full Text] [Related]
17. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
18. In vitro susceptibilities of clinical isolates of carbapenemase-producing Enterobacteriaceae to fosfomycin and tigecycline.
Choudhury S; Yeng JL; Krishnan PU
Clin Microbiol Infect; 2015 Oct; 21(10):e75-6. PubMed ID: 26086572
[No Abstract] [Full Text] [Related]
19. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
[TBL] [Abstract][Full Text] [Related]
20. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
